Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from PepGen Inc. ( (PEPG) ) is now available.
On October 1, 2025, PepGen Inc. updated its corporate presentation, highlighting the progress and potential of its investigational therapy PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1). The presentation emphasized the therapy’s favorable safety profile, significant splicing correction, and its designation as an Orphan Drug in both the U.S. and EU. The company’s EDO platform has shown promise in improving nuclear delivery of oligonucleotides, potentially overcoming previous limitations in the field. The announcement underscores PepGen’s commitment to addressing unmet medical needs and its strategic positioning in the biotech industry, with upcoming clinical trial results expected in 2026 and a cash runway into the second half of 2027.
The most recent analyst rating on (PEPG) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on PepGen Inc. stock, see the PEPG Stock Forecast page.
Spark’s Take on PEPG Stock
According to Spark, TipRanks’ AI Analyst, PEPG is a Underperform.
PepGen Inc.’s overall score reflects significant financial challenges, with limited revenue and continued losses. While technical indicators are mixed, the valuation remains unattractive due to negative earnings. Recent corporate events, including promising trial results and board expansions, offer some positive momentum but are insufficient to offset the financial concerns.
To see Spark’s full report on PEPG stock, click here.
More about PepGen Inc.
PepGen Inc. operates in the biotechnology industry, focusing on developing therapies for serious genetic neuromuscular and neurological diseases. The company leverages its EDO platform to enhance the delivery of therapeutic oligonucleotides, addressing conditions such as Myotonic Dystrophy Type 1 and exploring potential applications in other genetic conditions like Charcot-Marie-Tooth disease.
Average Trading Volume: 3,116,046
Technical Sentiment Signal: Buy
Current Market Cap: $297.2M
For an in-depth examination of PEPG stock, go to TipRanks’ Overview page.